Today AroCell publishes a short video interview with Michael Brobjer, CEO, and his reflections on his first months at Arocell.
The video is available through the link below, AroCell website, and on Financial Hearings web channel. The video is available in Swedish, subtitles will be added shortly.
For more information:
Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
This information was submitted for publication through the agency of Michael Brobjer, February 13, 2019, at 12:00.
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210™ ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90.